Skip to content
Clinical ResearchResearch compoundModerate evidence

Agmatine

Arginine-derived neuromodulator hitting NMDA and imidazoline targets, with a mood and pain support profile.

NootropicNeuromodulatorNeuromodulatorMood SupportNMDAGlutamatenoo.affects.neuroprotection

Pharmacology

ClassNeuromodulator · Mood Support
Primary targetImidazoline receptor and NMDA modulation
Targets4 receptor targets
Half-lifeShort (effects fade relatively quickly, so it is often split into several daily doses)
OnsetAbout 30-60 minutes, typically taken on an empty stomach
EvidenceModerate evidence
Affected systemsNMDAGlutamatenoo.affects.neuroprotection

Contents

WHAT IS AGMATINE?

Detailed overview

Agmatine is an endogenous neuromodulator formed by decarboxylation of arginine and sold as a dietary supplement in the form of agmatine sulfate. It acts on several targets at once: a weak NMDA receptor channel blocker, an imidazoline I1/I2 receptor agonist, an alpha-2 adrenoceptor modulator and an inhibitor of neuronal nitric oxide synthase, and it also behaves as an endogenous clonidine-displacing substance. Together these actions produce an antidepressant-like, analgesic and neuroprotective profile that is strongly supported by animal studies but only modestly in humans. A double-blind trial found agmatine sulfate effective in lumbar disc-associated radiculopathy, and an open-label pilot reported an antidepressant effect, but large confirmatory clinical trials are still lacking.

Mechanism

NMDA block + imidazoline agonism + nNOS inhibition

Evidence

Strong preclinical + small human pilots

Legal status

Dietary supplement (agmatine sulfate)

Receptor profile

  • NMDA receptors (channel block)Moderate
  • Imidazoline I1/I2 receptorsModerate
  • Alpha-2 adrenoceptorsWeak
  • Neuronal nitric oxide synthase (nNOS) inhibitionWeak

Safety

Side effects, stop signs, contraindications

Side effects · 4

  • Mild digestive upset (nausea, diarrhea, bloating), especially at higher doses
  • Mild blood pressure reduction from imidazoline and alpha-2 activity (possible dizziness)
  • Changes in appetite or satiety (via polyamine metabolism)
  • Uncertain long-term safety: human data are limited to small, short studies

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Low blood pressure or antihypertensive medication: additive hypotension possible
  • Combination with antidepressants (especially MAO inhibitors) requires medical supervision
  • Not an approved medicine: sold as a dietary supplement, not to treat disease

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Arginine-derived neuromodulator hitting NMDA and imidazoline targets, with a mood and pain support profile.

Telegram

Have a question about Agmatine?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC5H14N4
UpdatedJuly 10, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: July 10, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.